HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis.

AbstractBACKGROUND:
Variability in ultrafiltration influences prescriptions and outcomes in patients with kidney failure who are treated with peritoneal dialysis. Variants in AQP1, the gene that encodes the archetypal water channel aquaporin-1, may contribute to that variability.
METHODS:
We gathered clinical and genetic data from 1851 patients treated with peritoneal dialysis in seven cohorts to determine whether AQP1 variants were associated with peritoneal ultrafiltration and with a risk of the composite of death or technique failure (i.e., transfer to hemodialysis). We performed studies in cells, mouse models, and samples obtained from humans to characterize an AQP1 variant and investigate mitigation strategies.
RESULTS:
The common AQP1 promoter variant rs2075574 was associated with peritoneal ultrafiltration. Carriers of the TT genotype at rs2075574 (10 to 16% of patients) had a lower mean (±SD) net ultrafiltration level than carriers of the CC genotype (35 to 47% of patients), both in the discovery phase (506±237 ml vs. 626±283 ml, P = 0.007) and in the validation phase (368±603 ml vs. 563±641 ml, P = 0.003). After a mean follow-up of 944 days, 139 of 898 patients (15%) had died and 280 (31%) had been transferred to hemodialysis. TT carriers had a higher risk of the composite of death or technique failure than CC carriers (adjusted hazard ratio, 1.70; 95% confidence interval [CI], 1.24 to 2.33; P = 0.001), as well as a higher risk of death from any cause (24% vs. 15%, P = 0.03). In mechanistic studies, the rs2075574 risk variant was associated with decreases in AQP1 promoter activity, aquaporin-1 expression, and glucose-driven osmotic water transport. The use of a colloid osmotic agent mitigated the effects of the risk variant.
CONCLUSIONS:
A common variant in AQP1 was associated with decreased ultrafiltration and an increased risk of death or technique failure among patients treated with peritoneal dialysis. (Funded by the Swiss National Science Foundation and others.).
AuthorsJohann Morelle, Céline Marechal, Zanzhe Yu, Huguette Debaix, Tanguy Corre, Mark Lambie, Marion Verduijn, Friedo Dekker, Philippe Bovy, Pieter Evenepoel, Bert Bammens, Rafael Selgas, Maria A Bajo, Annemieke M Coester, Amadou Sow, Nicolas Hautem, Dirk G Struijk, Raymond T Krediet, Jean-Luc Balligand, Eric Goffin, Ralph Crott, Pierre Ripoche, Simon Davies, Olivier Devuyst
JournalThe New England journal of medicine (N Engl J Med) Vol. 385 Issue 17 Pg. 1570-1580 (10 21 2021) ISSN: 1533-4406 [Electronic] United States
PMID34670044 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2021 Massachusetts Medical Society.
Chemical References
  • AQP1 protein, human
  • Water
  • Aquaporin 1
Topics
  • Animals
  • Aquaporin 1 (genetics, metabolism)
  • Biological Transport (genetics, physiology)
  • Female
  • Genetic Variation
  • Genotype
  • Humans
  • Male
  • Mice
  • Mice, Knockout
  • Middle Aged
  • Models, Animal
  • Osmosis
  • Peritoneal Dialysis
  • Renal Insufficiency (genetics, mortality, therapy)
  • Risk Factors
  • Transcription, Genetic
  • Treatment Failure
  • Water (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: